Legend Biotech Q1 EPS Estimate Decreased by HC Wainwright

Key Points

• HC Wainwright cut its Q1 2026 EPS estimate for Legend Biotech to ($0.04) from $0.04 but kept a "Buy" rating and a $50 price target, while also forecasting FY2026 EPS of $0.42.
• Shares of LEGN trade around $18.21 (down ~1.8%) with a market cap of $3.37B, versus a consensus analyst rating of "Moderate Buy" and an average target of $58.31.
• Legend's latest quarter reported $0.01 EPS (beating estimates of ($0.17)) and $306.3M revenue (slightly below expectations), with revenue up 64.2% year-over-year but a negative net margin (~28.9%).

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) - Research analysts at HC Wainwright reduced their Q1 2026 EPS estimates for shares of Legend Biotech in a report issued on Monday, March 16th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.04) per share for the quarter, down from their prior estimate of $0.04. HC Wainwright has a "Buy" rating and a $50.00 price target on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech's FY2026 earnings at $0.42 EPS.

A number of other brokerages have also recently weighed in on LEGN. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Legend Biotech in a research report on Monday, December 29th. Cantor Fitzgerald cut their price objective on Legend Biotech from $75.00 to $74.00 and set an "overweight" rating on the stock in a research report on Wednesday, December 17th. Raymond James Financial reaffirmed an "outperform" rating on shares of Legend Biotech in a research report on Monday, February 23rd. Truist Financial set a $70.00 target price on Legend Biotech in a research note on Tuesday, March 10th. Finally, Royal Bank Of Canada dropped their target price on Legend Biotech from $66.00 to $62.00 and set an "outperform" rating on the stock in a report on Wednesday, March 11th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $58.31.

Legend Biotech Trading Down 1.8%

Shares of LEGN stock opened at $18.21 on Thursday. The company has a market cap of $3.37 billion, a PE ratio of -22.76 and a beta of 0.07. The company's fifty day simple moving average is $19.20 and its 200-day simple moving average is $25.87. Legend Biotech has a 52 week low of $16.24 and a 52 week high of $45.30.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last announced its quarterly earnings results on Tuesday, March 10th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.18. Legend Biotech had a negative net margin of 28.86% and a negative return on equity of 21.93%. The firm had revenue of $306.30 million for the quarter, compared to analysts' expectations of $310.21 million. During the same period in the previous year, the company posted $0.07 earnings per share. Legend Biotech's revenue was up 64.2% compared to the same quarter last year.

Institutional Trading of Legend Biotech

A number of hedge funds have recently made changes to their positions in LEGN. Clearstead Advisors LLC boosted its stake in Legend Biotech by 76.5% during the 3rd quarter. Clearstead Advisors LLC now owns 847 shares of the company's stock valued at $28,000 after acquiring an additional 367 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of Legend Biotech by 171.9% during the third quarter. Parallel Advisors LLC now owns 1,047 shares of the company's stock worth $34,000 after purchasing an additional 662 shares during the last quarter. OFI Invest Asset Management lifted its position in shares of Legend Biotech by 102.6% during the third quarter. OFI Invest Asset Management now owns 1,228 shares of the company's stock worth $40,000 after purchasing an additional 622 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in Legend Biotech by 1,730.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,569 shares of the company's stock worth $78,000 after purchasing an additional 3,374 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Legend Biotech in the second quarter worth about $78,000. Institutional investors and hedge funds own 70.89% of the company's stock.

About Legend Biotech

Legend Biotech NASDAQ: LEGN is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company's lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.